Texas Flood Victims Offered 30 Days Free Storage at 37 U-Haul Centers
U-Haul has added 21 centers in metro Austin to its 16 centers in the San Antonio area that are now offering a month of free storage services to Texas flood victims in need of assistance during the recovery process.
Share
The Guadalupe River's catastrophic flooding has tragically resulted in the loss of life. Intense rains also produced property damage for many residents.
Access to dry and secure self-storage units and portable storage containers can assist communities during the clean-up and recovery process after natural disasters.
By adding 21 centers in metro Austin to 16 stores in the San Antonio area, there are 37 U-Haul-owned and -operated facilities now participating in the goodwill offer.
The U-Haul disaster relief program applies to new self-storage and U-Box rentals and is based on availability at participating facilities. The U-Box portable container offer is for on-site storage at Company centers.
People seeking more information on the 30 days free storage offer or needing to arrange services can contact their nearest regional office or stop by a U-Haul self-storage facility in the cities below:
U-Haul Co. of North Austin (13 stores)
Store locations: Austin, Cedar Park, Copperas Cove, Killeen, Pflugerville, Round Rock, Temple
(512) 865-4154
U-Haul Co. of South Austin (8 stores)
Store locations: Austin
(512) 331-7705
U-Haul Co. of San Antonio East (7 stores)
Store locations: New Braunfels, San Antonio
(210) 731-2805
U-Haul Co. of San Antonio West (9 stores)
Store locations: San Antonio
(210) 569-0962
In addition to its 30 days free self-storage disaster relief program, U-Haul is proud to be at the forefront of aiding communities in times of need as an official American Red Cross Disaster Responder.
About U-HAUL
Celebrating our 80th anniversary in 2025, U-Haul is the No. 1 choice of do-it-yourself movers with more than 24,000 rental locations across all 50 states and 10 Canadian provinces. The U-Haul app makes it easy for customers to use U-Haul Truck Share 24/7 to access trucks anytime through the self-dispatch and -return options on their smartphones with our patented Live Verify technology. Our customers' patronage has enabled the U-Haul fleet to grow to 193,900 trucks, 138,200 trailers and 40,300 towing devices. U-Haul is the third largest self-storage operator in North America and offers 1,060,000 rentable storage units and 92.0 million square feet of self-storage space at owned and managed facilities. U-Haul is the top retailer of propane in the U.S. and the largest installer of permanent trailer hitches in the automotive aftermarket industry. Get the U-Haul app from the App Store or Google Play.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
2 hours ago
- USA Today
US economy poised to slow as Trump's tariffs hit consumers
The cloud of uncertainty that has hovered over the U.S. economy the first half of 2025 threatens to unleash a thunderstorm that dampens growth in the second half as President Donald Trump's higher tariffs hit consumers and his immigration crackdown rocks the job market. While growth was already poised to slow, Trump on July 10 increased the risks of a more pronounced pullback by announcing plans to raise the tariff rate on many Canadian imports from 25% to 35% and impose a blanket 15% to 20% duty on most other countries, up from 10%. On July 12, the tariff threats ramped up again with Trump announcing 30% tariffs on all imports from Mexico and the European Union. In the spring, Trump announced a 90-day pause on high double-digit reciprocal tariffs for China and many other countries, easing recession fears and reversing a stock market sell-off. This week, White House officials extended the reprieve to August 1 to provide more time for negotiations. But in recent days, Trump again has ratcheted up his trade threats, unveiling plans for a 50% tariff on imported copper, 50% on all shipments from Brazil and high fees for 14 countries that don't reach a deal with the U.S. by August 1. Already in effect: a 50% levy on metals, 25% on cars and 30% on China, in addition to the blanket 10% charge that appears poised to rise sharply. The Dow Jones Industrial Average tumbled nearly 280 points July 11 on Trump's latest tariff threats. 'Risks are intensifying that we may see much higher tariff rates, with consequent effects on inflation and growth,' said Jonathan Millar, senior U.S. economist at Barclays. Just 42% of CEOs of small and midsize companies plan to add to their staffs in the next year, lowest on record dating to 2003, according to a June survey by Vistage, a CEO networking group. How close is the US to a recession? Gregory Daco, chief economist at EY-Parthenon, has lowered his odds of a recession this year to 35% from 50% but said the chances of a downturn would climb above 50% if Trump reverts to the tariffs he rolled out in early April. Even without the harsher import fees Trump recently announced, economists have been predicting a notable slowdown in growth the rest the year. 'We're carrying much less economic momentum, with a softening labor market trend, inflation about to reaccelerate and income (growth) more subdued,' Daco said. Will tariffs lead to inflation? Forecasters have been surprised that tariffs haven't yet had a significant effect on inflation. Daco said that's partly because manufacturers and retailers stocked up on foreign goods in February and March, before the fees took effect. Also, he said, companies have been routing products through bonded warehouses that delay tariff payments. U.S. businesses and foreign exporters have absorbed much of the costs. And higher prices from tariffs don't immediately show up in inflation reports, such as the consumer price index. But all those tactics can delay the inevitable only so long, Daco said. 'As inventory buffers thin, bonded warehouse timelines expire and cost absorption runs its course, price pressures will start surfacing more clearly into the second half of 2025,' he wrote in a note to clients. Before Trump escalated the trade conflicts, many economists said the levies have pushed the average U.S. tariff rate from about 3% to 15%, a rise that would drive the Federal Reserve's preferred annual inflation measure from 2.7% to about 3.3% by the end of the year. How does immigration affect the economy? Meanwhile, an immigration surge that has bolstered the U.S. labor supply and job growth the past few years 'is about to go into reverse,' JPMorgan Chase said in a research note last week. The Trump administration is ending provisions that temporarily protected immigrants who lack permanent legal status from deportations for humanitarian reasons. That will likely cause 1.8 million migrants, including about 1.1 million workers, to lose their legal status in the second half of the year, JPMorgan Chase said. Especially affected are industries such as agriculture, construction and hospitality. Already, annual net immigration to the U.S. has slowed from about 3 million the past few years to an annual rate that's set to reach 500,000 by year's end, according to the Congressional Budget Office and economists. That compares to a rate of 900,000 a year before the pandemic. While the slowdown is projected to reduce job growth, forecasters reckoned that would take some time because many immigrants who arrived in recent waves are still settling into jobs. But the spike in deportations could quickly slow America's job engine within months, JPMorgan Chase said. How is the economy doing right now? The economy shrank at an annual rate of 0.5% in the first quarter but forecasters said that was mostly because the flood of imports from companies stocking up had to be subtracted from output (since they're made in foreign countries). Private domestic demand, a more telling measure of the economy's underlying health, increased a solid 1.9%. And economists estimate the government later this month will report 2% growth in the second quarter, according to those surveyed by Wolters Kluwer Blue Economic Indicators. But those forecasters expect quarterly growth to average just 0.7% the second half of the year, in line with Millar's estimate. and above the 0.5% gain Daco projects. That's close to stall speed. From the fourth quarter of 2024 to the fourth quarter of 2025, Millar estimates the economy will grow a meager 0.5%, compared to 2.5% the prior year. Here's a breakdown: Consumer spending Resilient households have propped up the economy the past few years but the threat of higher prices from tariffs has led Americans to rein in their spending, Daco and Millar said. Now, the actual pass-through of the fees into prices will likely have a more tangible impact on consumption, Daco said. Consumers especially have been cutting back on discretionary purchases, such as recreational services, travel and dining out. Income also has moderated, with average annual wage growth falling from about 6% in early 2022 to 3.7% in June. After adjusting for inflation, consumer spending fell 0.3% in May and is expected to rise just 0.7% the second half of the year, according to the Wolters Kluwer survey. Consumption makes up 70% of economic activity. The job market Average monthly job growth has slowed to 130,000 so far this year from 168,000 in 2024. Companies have sharply cut back hiring amid tariff-related uncertainty but remain hesitant to lay off workers following severe pandemic-related labor shortages, Millar said. But Daco said more companies are shedding workers through attrition and retirement, as well as targeted layoffs. Tracy Marlowe, CEO of Creative Noggin, a marketing company based in San Antonio, Texas, said sales were flat last year amid election-related uncertainty. After the election, clients began making requests for new campaigns but pulled back again in early 2025 amid Trump's on-again, off-again tariffs. Marlowe had been planning to add a full-time employee to her staff of 20 later this year but has decided to hold off. Clients 'are just trying to figure out how to stay alive,' she said. "I'll hire once I need somebody." Coping with the Great Recession and the COVID-19 downturn was easier, Marlowe said, because she knew the roadmap for recovery. By contrast, the trade war 'has been a constantly changing roller coaster... It makes it very difficult to predict what's next.' The immigration crackdown is set to slow job growth further, Daco said. Business investment Business capital spending surged in the first quarter as firms stocked up ahead of tariffs. But the economists surveyed by Wolters Kluwer expect outlays to fall in the second, third and fourth quarters. Companies already leery about ramping up spending amid the uncertainty are likely to hunker down further as the import costs they absorb squeeze profits, Daco said. Housing Housing starts fell 9.8% in May and single-family starts are down 16% since February, according to Oxford Economics. 'Elevated interest rates and higher building material costs due to tariffs will make construction less profitable,' Oxford said in a research note.
USA Today
2 hours ago
- USA Today
Nvidia reaches historic $4 trillion valuation, leads Wall Street's AI charge
Nvidia notched a market capitalization of $4 trillion on Wednesday, making it the first public company in the world to reach the milestone and solidifying its position as one of Wall Street's most-favored stocks. Shares of the leading chip designer rose as much as 2.5% to an all-time high of $164, benefiting from the ongoing surge in demand for artificial intelligence technologies. Nvidia's soaring market value underscores Wall Street's confidence in the rapid growth of AI, with the company's high-performance chips forming the backbone of this technological advance. The stock's recent rally follows a sluggish start to the year, when the emergence of a Chinese discount artificial intelligence model developed by DeepSeek shook confidence in stocks linked to the sector. "It started out as being a gaming chipmaker and then a crypto mining chipmaker and now as a chipmaker for artificial intelligence computing power," said Art Hogan, chief market strategist at B Riley Wealth. "It is continuing to move forward and be a clear early winner of artificial intelligence." Nvidia achieved a $1 trillion market value for the first time in June 2023 and tripled it in about a year, faster than Apple AAPL.O and Microsoft MSFT.O, the only other U.S. firms with a market value of more than $3 trillion. Microsoft is the second biggest U.S. company, with a market capitalization of $3.75 trillion. Its shares were last up 1.3% at $503. Nvidia has rebounded about 74% from its lows in April, when global markets were jolted from U.S. President Donald Trump's tariff volley. Optimism around trade partners reaching deals with the U.S. have lifted stocks of late, with the S&P 500 .SPX hitting an all-time high. Nvidia holds a 7.3% weight on the S&P 500, the biggest on the index. Other tech behemoths, Apple and Microsoft, account for around 7% and 6%, respectively. The company is worth more than the combined value of the Canadian and Mexican stock markets, according to LSEG data, and exceeds the total value of all publicly listed companies in the UK. Its stock trades at a 12-month forward price-to-earnings ratio of 32, below its three-year average of 37, according to data compiled by LSEG. It reported a total revenue of $44.1 billion in the first quarter, marking a 69% jump from a year ago along with a profit of 81 cents a share. For the second quarter, Nvidia expects revenue of $45 billion, plus or minus 2%. It will report second-quarter results on August 27. Including the session's gains, Nvidia is up more than 22% this year compared to a nearly 15% rise in the Philadelphia SE Semiconductor Index .SOX. Reporting by Shashwat Chauhan and Johann M Cherian in Bengaluru; Editing by Chuck Mikolajczak and Arun Koyyur
Business Insider
2 hours ago
- Business Insider
Raymond James Predicts Up to ~760% Surge for These 2 ‘Strong Buy' Stocks
With the summer of 2025 in full swing, all eyes are on President Trump's trade moves once again. Over the past week, Trump announced a 35% tariff on most Canadian imports, set a 50% tariff on select Brazilian goods, and warned that a broader set of tariff hikes for other major trading partners could take effect as soon as August 1 if new trade agreements aren't reached. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Naturally, all this has stirred up some uncertainty – especially for investors trying to read the tea leaves on inflation, supply chains, and overall market direction. And yet, Raymond James CIO Larry Adam sees plenty of reason for optimism when looking at the bigger picture. 'For investors, market ups and downs are nothing new. Despite interim setbacks, the S&P 500 has delivered a robust average annual return of ~11% since 1985. Bull markets historically last six times longer than bear markets and produce returns five times more powerful. The takeaway? Stay focused on the long term,' Adam notes. That long-term perspective leads to a clear track, and Adam elaborates on it, saying, 'We continue to favor U.S. equities, where the outlook remains brighter… We expect two rate cuts by year end and two more in 2026, helping growth pick up to 1.5% next year. Trump's 'One Big Beautiful Bill' could also provide a modest boost, even if it adds to the deficit.' Against this backdrop, Raymond James analysts have zeroed in on two stocks they believe are set for substantial growth in the coming year – including one with a potential upside as high as 760%. As if that weren't compelling enough, both names also earn a Strong Buy rating from the analyst consensus, according to the TipRanks database. Let's break down what's behind the bullish sentiment. Achieve Life Sciences (ACHV) We'll start with a stock that is bursting with upside potential. Achieve Life Sciences is both a biopharmaceutical company and a penny stock – two niches known for their ability to deliver outsized returns. Central to the company's growth story is its lead program: developing treatments for nicotine dependence. Nicotine, the key addictive ingredient in tobacco products, has been connected to multiple health problems, including recurrent headaches, high blood pressure, dangerous blood clotting, sleep disorders, and changes in heart rhythm. The most common way that people satisfy their nicotine cravings is through smoking, which brings along its own array of health issues, from COPD to various cancers. This isn't just a health challenge – it's a massive market opportunity. There are 29 million smokers in the US alone, some 16 million Americans living with smoking-related illnesses, and globally, about 8 million smoking-related deaths each year. Achieve is targeting the problem with the development of cytisinicline, a naturally derived drug candidate designed to reduce withdrawal symptoms and make it easier to quit smoking or vaping. What sets cytisinicline apart is its robust clinical profile. The drug has delivered strong Phase 3 data on smoking cessation, with a favorable safety record to match. In the ORCA-2 and ORCA-3 trials, cytisinicline consistently produced statistically significant improvements in abstinence rates versus placebo. In ORCA-3, 30.3% of participants in the 12-week arm achieved continuous abstinence during weeks 9 to 12, compared to 9.4% with placebo, and about 20.5% remained abstinent through week 24 versus 4.2% for placebo. The safety profile was favorable, with mostly mild to moderate side effects and no treatment-related serious adverse events. These findings were reinforced by the ORCA-OL trial, where the independent DSMC's third safety review identified no concerns with long-term cytisinicline use. Now, Achieve is gearing up for the next phase: FDA approval and commercial launch. At the end of June, the company submitted a New Drug Application (NDA) to the FDA. If approved, cytisinicline will become the first FDA-approved drug therapy for nicotine addiction in the past two decades. To support its commercialization efforts, Achieve recently announced a strategic partnership with Omnicom and has raised about $45 million. Moreover, Achieve is not stopping with traditional smokers. The company is advancing cytisinicline as a potential treatment for nicotine dependence in e-cigarette users as well. In the Phase 2 ORCA-V1 trial, cytisinicline produced higher quit rates than placebo among individuals seeking to quit vaping, with no serious adverse events reported. Following these results, Achieve held an end-of-Phase 2 meeting with the FDA and reached agreement on the design of a pivotal Phase 3 trial for vaping cessation. With that green light, the company plans to kick off the ORCA-V2 Phase 3 study in the first half of 2026. Put it all together – the compelling data, the unmet need, the imminent FDA milestone, and a bargain-bin $2.32 share price – and it's no wonder Raymond James analyst Gary Nachman thinks now is the time to get in on the action. 'Our Strong Buy rating is supported by a significant unmet need still in the [nicotine addiction] market that is a major global public health concern, with current options resulting in very low quit rates. Cytisinicline has a compelling clinical profile with strong Phase 2/3 data. Cytisinicline shows high smoking cessation quit rates and a favorable safety profile compared to PFE's Chantix (peak sales $1.1B) that is now generic. Cytisinicline has a proven mechanism that is similar to Chantix, but is naturally derived and more selective resulting in fewer AEs, has 50+ years of safe use in E. Europe, and now a submitted NDA with a de-risked regulatory pathway,' Nachman opined. 'There is a large opportunity in smoking cessation that is ripe for the taking and an expanded partnership with Omnicom should help with the US launch, and potentially big upside from vaping as well… A partnership/acquisition to maximize value is possible,' the analyst added. All of this helps explain Nachman's Strong Buy rating on ACHV, which comes with a $20 price target. If his thesis plays out, investors could be looking at a whopping ~760% gain over the next 12 months. (To watch Nachman's track record, click here) And it's not just Nachman who sees big upside here. The broader analyst community is similarly upbeat: in the past 3 months, ACHV has picked up 4 Buy ratings with no Holds or Sells, earning it a consensus Strong Buy status on Wall Street. Meanwhile, the average price target of $15.25 points to a 557% upside from current levels. (See ACHV stock forecast) Avidity Biosciences (RNA) The next stock catching Raymond James' attention is Avidity Biosciences, a clinical-stage biotech firm aiming to develop a new class of RNA therapeutics – drug candidates designed to tackle the root genetic causes behind a variety of serious diseases. The company is building its pipeline using its proprietary Antibody Oligonucleotide Conjugates platform, or AOC. This platform blends the targeting abilities of monoclonal antibodies with the gene-silencing power of oligonucleotide therapies, creating agents that can home in on disease drivers at the genetic level with notable selectivity and precision. Through this approach, Avidity aims to address conditions that have long eluded effective treatment. At present, the company's primary targets are skeletal muscle diseases, especially within the muscular dystrophy class. Avidity has developed a robust research pipeline, which includes three lead drug candidates that are advancing through clinical trials. These three programs – Del-zota, Del-desiran, and Del-brax – are each aimed at specific muscle disorders: Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD), respectively. Each of these candidates has shown solid progress. Del-zota, Avidity's program for Duchenne muscular dystrophy, has demonstrated strong increases in exon skipping and dystrophin production, along with an encouraging safety profile. Based on these results, the company expects to submit its first Biologics License Application (BLA) for del-zota by year-end. Meanwhile, del-desiran has delivered impressive data in early clinical trials, with patients experiencing not only reductions in toxic RNA but also meaningful signs of functional improvement. These encouraging results have been further supported by the ongoing MARINA-OLE extension study, which continues to show sustained benefit with longer-term treatment. On the strength of these findings, the program advanced into the pivotal Phase 3 HARBOR trial. The company previously noted that enrollment would be completed by mid-2025, setting the stage for comprehensive data readouts in the first half of 2026. Rounding out the pipeline, the del‑brax program for FSHD is also advancing steadily. Initial data from the FORTITUDE study demonstrated significant reductions in DUX4 gene expression, and with an FDA‑validated accelerated approval pathway now in place, Avidity launched the pivotal FORWARD Phase 3 trial. This global, 18‑month, randomized, placebo‑controlled study is expected to deliver topline results by H2 2026. With all three programs advancing toward key clinical and regulatory milestones, Raymond James analyst Martin Auster sees strong prospects for success here. 'We have high conviction in del-zota (DMD44) to become the first approved drug from Avidity's antibody oligonucleotide conjugate (AOC) platform. Del-desiran (DM1) has been derisked through Ph1/2 biomarker and functional data, and a positive Ph 3 outcome in ~H1 2026 could be transformative for Avidity given del-desiran's first-mover potential and a large DM1 market opportunity (~$5B+ TAM). Del-brax has an even larger potential first-mover advantage in FSHD (opportunity for a strong competitive moat); we project accelerated approval in 2027 supported by cDUX biomarker data and 12-month placebo-controlled functional data,' Auster stated. Auster's high conviction is reflected in his Strong Buy rating on RNA and a $65 price target, which suggests a potential 107% upside from current levels. (To watch Auster's track record, click here) That's far from the only upbeat take on this stock. RNA enjoys a Strong Buy consensus, based on 18 recent analyst ratings – with 17 Buys and just a single Hold. At its current price of $31.45, the stock's average target price of $64.44 suggests RNA could surge ~105% in value over the next year. (See RNA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
